natgillin/translations-raw huggingface dataset:
Co-administration of Tybost with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of cobicistat and consequently that of atazanavir or darunavir being boosted, leading to loss of therapeutic effect and possible development of resistance.
Istovremena primjena lijeka Tybost s lijekovima koji su umjereni do jaki induktori CYP3A može za posljedicu imati smanjenu koncentraciju kobicistata u plazmi i posljedično smanjenje pojačanja atazanavira ili darunavira što uzrokuje gubitak terapijskog učinka i mogući razvoj rezistencije.
Co-administration of Tybost with medicinal products that are strong inducers of CYP3A (such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, phenytoin) may result in decreased plasma concentrations of cobicistat and consequently that of atazanavir or darunavir being boosted, leading to loss of therapeutic effect and possible development of resistance (see section 4.3).
Istovremena primjena lijeka Tybost i lijekova koji su jaki induktori CYP3A (kao što su gospina trava [Hypericum perforatum], rifampicin, karbamazepin, fenobarbital i fenitoin), može za posljedicu imati smanjene plazmatske koncentracije kobicistata te posljedično smanjenja pojačanja atazanavira ili darunavira, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije (vidjeti dio 4.3).
Co-administration of Tybost with medicinal products that are substrates of these transporters can result in increased plasma concentrations of the co-administered medicinal products (see section 4.4).
Istovremena primjena lijeka Tybost sa lijekovima koji su supstrati tih transportera može za posljedicu imati povećane koncentracije istovremeno primijenjenih lijekova u plazmi (vidjeti dio 4.4).
Co-administration of Tybost with medicinal products that induce CYP3A is contraindicated or is not recommended (see sections 4.3 and 4.5) because decreased plasma concentrations of cobicistat could result in plasma levels that are insufficient to achieve adequate pharmacoenhancement of atazanavir or darunavir.
Istovremena primjena lijeka Tybost s lijekovima koji induciraju CYP3A kontraindicirana je ili se ne preporučuje (vidjeti dijelove 4.3 i 4.5) jer smanjene koncentracije kobicistata u plazmi mogu za posljedicu imati razine kobicistata u plazmi koje nisu dostatne za postizanje odgovarajućeg farmakokinetičkog pojačanja atazanavira ili darunavira.
Co-administration of Tybost with medicinal products that inhibit CYP3A may decrease the clearance of cobicistat, resulting in increased cobicistat plasma concentrations (see section 4.5).
Istovremena primjena lijeka Tybost s lijekovima koji inhibiraju CYP3A može smanjiti klirens kobicistata, što može za posljedicu imati povećane koncentracije kobicistata u plazmi (vidjeti dio 4.5).
Co-administration of Tybost with medicinal products that inhibit CYP3A may result in increased plasma concentration of cobicistat.
Istovremena primjena lijeka Tybost s lijekovima koji inhibiraju CYP3A može za posljedicu imati povećanu koncentraciju kobicistata u plazmi.
Co-administration of Tybost with sildenafil for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
Istovremena primjena lijeka Tybost i sildenafila za liječenje plućne arterijske hipertenzije je kontraindicirana (vidjeti dio 4.3).
Co-administration of Tyverb with known inducers of CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or Hypericum perforatum [St John’s Wort]) should be avoided.
Potrebno je izbjegavati istovremenu primjenu lijeka Tyverb s poznatim induktorima CYP3A4 (npr. rifampicin, rifabutin, karbamazepin, fenitoin ili gospina trava).
Co-administration of Tyverb with moderate inhibitors of CYP3A4 should proceed with caution and clinical adverse reactions should be carefully monitored.
Istovremenu primjenu lijeka Tyverb s umjerenim inhibitorima CYP3A4 potrebno je nastaviti s oprezom, uz pažljivo praćenje kliničkih nuspojava.
Co-administration of Tyverb with orally administered medicinal products with narrow therapeutic windows that are substrates of CYP3A4 (e.g. cisapride, pimozide and quinidine) should be avoided (see sections 4.4 and 5.2).
Potrebno je izbjegavati istovremenu primjenu lijeka Tyverb s lijekovima za peroralnu primjenu uske terapijske širine koji su supstrati CYP3A4 (npr. cisaprid, pimozid i kinidin) (vidjeti dijelove 4.5 i 5.2).
Co-administration of umeclidinium/vilanterol with other long-acting muscarinic antagonists, long-acting beta2-adrenergic agonists or medicinal products containing either of these agents has not been studied and is not recommended as it may potentiate known inhaled muscarinic antagonist or beta2-adrenergic agonist adverse reactions (see section 4.4 and section 4.9).
Istodobna primjena umeklidinija/vilanterola s drugim dugodjelujućim muskarinskim antagonistima, dugodjelujućim beta2-adrenergičkim agonistima ili lijekovima koji sadrže jednu od tih dviju djelatnih tvari nije ispitivana i stoga se ne preporučuje jer može potencirati poznate nuspojave koje se javljaju pri inhalaciji muskarinskih antagonista ili beta2-adrenergičkih agonista (vidjeti dijelove 4.4 i 4.9).
Co-administration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
Istodobna primjena valdekoksiba i litija izazvala je značajno smanjenje serumskog klirensa (25%) i bubrežnog klirensa (30%) litija uz 34% veću serumsku izloženost u odnosu na primjenu samo litija.
Co-administration of valdecoxib with glibenclamide (CYP3A4 substrate) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glibenclamide.
Istodobna primjena valdekoksiba s glibenklamidom (supstrat CYP3A4) nije utjecala niti na farmakokinetiku (izloženost) niti na farmakodinamiku (razine glukoze i inzulina u krvi) glibenklamida.
Co-administration of Viekirax with or without dasabuvir with medicinal products that are primarily metabolized by UGT1A1 result in increased plasma concentrations of such medicinal products; routine clinical monitoring is recommended for narrow therapeutic index medicinal products (i.e. levothyroxine).
Istodobna primjena lijeka Viekirax, s dasabuvirom ili bez njega, i lijekova koji se prvenstveno metaboliziraju posredstvom UGT1A1 povećava koncentracije tih lijekova u plazmi; preporuča se rutinsko kliničko praćenje za lijekove s uskim terapijskim indeksom (tj. levotirkosin).
Co-administration of Vitekta with moderate CYP3A inducers (including, but not limited to, efavirenz and bosentan) is not recommended (see section 4.5).
Ne preporučuje se istovremena primjena lijeka Vitekta i umjerenih induktora CYP3A (uključujući, bez ograničenja, efavirenz i bosentan) (vidjeti dio 4.5).
Co-administration of Vitekta with strong CYP3A inducers (including St. John’s wort [Hypericum perforatum], rifampicin, carbamazepine, phenobarbital and phenytoin) is contraindicated (see sections 4.3 and 4.5).
Kontraindicirana je istovremena primjena lijeka Vitekta i jakih induktora CYP3A (uključujući gospinu travu [Hypericum perforatum], rifampicin, karbamazepin, fenobarbital i fenitoin) (vidjeti dijelove 4.3 i 4.5).
Co-administration of voriconazole
Istodobna primjena
Co-administration of voriconazole
istodobno s vorikonazolom u
Co-administration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.5 and 4.3).
Treba izbjegavati istodobnu primjenu vorikonazola i niske doze ritonavira (100 mg dvaput na dan) osim ako se procijeni da omjer koristi i rizika za bolesnika opravdava primjenu vorikonazola (vidjeti dijelove 4.3 i 4.5).
Co-administration of Yondelis with potent inhibitors of the enzyme CYP3A4 should be avoided (see section 4.5).
Mora se izbjegavati istodobna primjena Yondelisa s potentnim inhibitorima enzima CYP3A4 (vidjeti dio 4.5).
Co-administration of Zydelig with moderate or strong CYP3A inducers such as rifampicin, phenytoin, St. John’s wort, or carbamazepine should be avoided as this may result in decreased efficacy (see section 4.4).
Istovremenu primjenu Zydeliga s umjerenim ili jakim CYP3A induktorima kao što su rifampicin, fenitoin, gospina trava ili karbamazepin treba izbjegavati, jer može dovesti do smanjenja djelotvornosti (vidjeti dio 4.4).
Co-administration resulted in increases in hydroxy- and desmethyl-dabrafenib AUC (increases of 82% and 68%, respectively).
Istovremena primjena rezultirala je porastom AUC-a hidroksi- i desmetil-dabrafeniba (porast od 82% odnosno 68%).
Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.
Treba izbjegavati istodobnu primjenu osim ako se smatra da potencijalna korist nadmašuje rizik.
Co-administration should be done in a setting
Smiju se istodobno primjenjivati u okruženju u
Co-administration was not associated with higher rates of local or systemic reactions compared to administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics alone.
Istodobna primjena nije bila povezana s većim stopama lokalnih ili sistemskih reakcija u usporedbi s primjenom Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics samog.
Co-administration with
Istodobna primjena s lijekom
Co-administration with
Kombinacija avanafila i lijeka
co-administration with an inhibitor
istodobne primjene s inhibitorom
Co-administration with antiretroviral medicinal products
Istodobna primjena s antiretrovirusnim lijekovima
Co-administration with boceprevir or telaprevir has the potential to adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide, therefore co-administration of Descovy and boceprevir or telaprevir is not recommended.
Istodobna primjena s boceprevirom ili telaprevirom moţe štetno djelovati na intracelularnu aktivaciju i kliničku antivirusnu djelotvornost tenofoviralafenamida te se stoga istodobna primjena lijeka Descovy i boceprevira ili telaprevira ne preporučuje.
Co-administration with boosted
Istodobna primjena s pojačanom
Co-administration with boosted PREZISTA may lead to a substantial increase in exposure to ticagrelor.
Istodobna primjena s pojačanom PREZISTOM može dovesti do znatnog povećanja izloženosti tikagreloru.
Co-administration with cobicistat can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.4).
Istovremena primjena s kobicistatom može povećati plazmatske koncentracije lijekova koje metabolizira CYP2D6 (vidjeti dijelove 4.3 i 4.4).
Co-administration with cobicistat can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
Istovremena primjena s kobicistatom može povećati koncentracije lijekova u plazmi koje metabolizira CYP2D6 (vidjeti dijelove 4.3 i 4.5).
Co-administration with cobicistat may result in increased sildenafil, tadalafil and vardenafil plasma concentrations, which may result in PDE-5 inhibitor-associated adverse reactions.
Istovremena primjena kobicistata može za posljedicu imati povećane koncentracije sildenafila, tadalafila i vardenafila u plazmi, što može dovesti do nuspojava povezanih s inhibitorom PDE-5.
Co-administration with cobicistat may result in increased sildenafil, tadalafil and vardenafil plasma concentrations, which may result in PDE-5 inhibitor-associated adverse reactions.
Koncentracije ovih sedativa/hipnotika mogu se povećati kod istovremene primjene s kobicistatom.
Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly increased risk of severe adverse reactions.
Treba izbjegavati istodobnu primjenu stiripentola s tvarima uskog terpijskog indeka koje su supstrati CYP3A4 zbog povećanog rizika od teških nuspojava.
Co-administration with dabigatran
Istodobna primjena s dabigatranom
Co-administration with darunavir boosted with low dose ritonavir may lead to a substantial increase in exposure to ticagrelor
Istodobna primjena s darunavirom pojačanim s niskom dozom ritonavira može dovesti do znatnog povećanja izloženosti tikagreloru
Co-administration with didanosine due to the potential for serious and/or life-threatening events notably lactic acidosis, liver function abnormalities, pancreatitis and peripheral neuropathy (see sections 4.4 and 4.5).
Istovremena primjena s didanozinom zbog mogućih ozbiljnih i /ili po život opasnih događaja, osobito laktična acidoza, poremećaji funkcije jetre, pankreatitis, i periferna neuropatija (vidjeti dijelove 4.4.i 4.5.)
Co-administration with EVOTAZ
Istodobna primjena s lijekom
Co-administration with EVOTAZ may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije salmeterola i pojačati nuspojave povezane sa salmeterolom.
Co-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold and increased M1 to a lesser extent than ivacaftor.
Istovremena primjena s flukonazolom, umjereno jakim inhibitorom CYP3A, povećala je izloženost ivakaftoru 3 puta, i povećala izloženost M1 u manjoj mjeri nego ivakaftoru.
Co-administration with food has no effect on plasma concentrations.
Davanje istovremeno s hranom nema nikakvog učinka na koncentracije u plazmi.
Co-administration with food results in a marked decrease in systemic glycopyrronium exposure (see section 4.2.).
Kod istovremenog uzimanja s hranom dolazi do značajnog smanjenja sistemske izloženosti glikopironiju (vidjeti dio 4.2.).
Co-administration with Gazyvaro had no effect on the pharmacokinetics of bendamustine, FC, chlorambucil or the individual components of CHOP.
Istodobna primjena s lijekom Gazyvaro nije utjecala na farmakokinetiku bendamustina, protokola FC, klorambucila ni pojedinačnih sastavnica protokola CHOP.
Co-administration with Genvoya may lead to decreased elvitegravir and/or cobicistat exposures and loss of therapeutic effect and development of resistance.
Istodobna primjena s lijekom Genvoya može dovesti do smanjene izloženosti elvitegraviru i/ili kobicistatu te do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration with Genvoya may result in increased plasma concentrations of salmeterol, which is associated with the potential for serious or life-threatening adverse reactions.
Istodobna primjena lijeka Genvoya može za posljedicu imati povećane koncentracije salmeterola u plazmi, što je povezano s potencijalno teškim ili životno opasnim nuspojavama.
Co-administration with herbal preparations containing St John’s wort (Hypericum perforatum) (see section 4.5).
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
Co-administration with herbal preparations containing St. John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz (see section 4.5).
Istovremena primjena s biljnim preparatima koji sadržavaju gospinu travu (Hypericum perforatum) zbog rizika smanjenih koncentracija plazme i smanjenih kliničkih učinaka efavirenza (vidjeti dio 4.5).
Co-administration with high dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose. (see section 4.5, for lower doses see section 4.4).
Istodobna primjena s visokom dozom ritonavira (400 mg i više dvaput na dan), jer ritonavir u toj dozi značajno smanjuje koncentraciju vorikonazola u plazmi zdravih ispitanika (vidjeti dio 4.5; za manje doze vidjeti dio 4.4).
Co-administration with high-dose ritonavir (>200 mg every 12 hours) (see section 4.5).
Istodobna primjena s visokim dozama ritonavira (200 mg svakih 12 sati) (vidjeti dio 4.5).
Co-administration with hormonal contraceptives
Istodobna primjena s hormonskim kontraceptivima
Co-administration with inducers of cytochrome P450 3A (CYP3A) or P-glycoprotein (P-gp), such as efavirenz, phenytoin, carbamazepine, bosentan, etravirine, modafinil or St. John’s wort (Hypericum perforatum).
Istodobna primjena s induktorima izoenzima 3A citokroma P450 (CYP3A) ili P-glikoproteina (P-gp), poput efavirenza, fenitoina, karbamazepina, bosentana, etravirina, modafinila ili gospine trave (Hypericum perforatum).
Co-administration with inducers of metabolic enzymes
Istodobna primjena s induktorima metaboličkih enzima
Co-administration with inhibitors of organic anion transporting polypeptide 1B (OATP1B), such as rifampicin, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cobicistat or ciclosporin.
Istodobna primjena s inhibitorima polipeptidnog prijenosnika organskih aniona 1B (engl. organic anion transporting polypeptide 1B, OATP1B), poput rifampicina, atazanavira, darunavira, lopinavira, sakvinavira, tipranavira, kobicistata ili ciklosporina.
co-administration with itraconazole
istodobne primjene s itrakonazolom
Co-administration with ketoconazole (400 mg) in healthy volunteers increased mean vilanterol AUC(0-t) and Cmax, 65% and 22% respectively.
Istodobna primjena s ketokonazolom (400 mg) u zdravih dobrovoljaca povećala je srednju vrijednost AUC(0-t) vilanterola za 65%, a srednju vrijednost Cmax, za 22%.
Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5-fold and increased hydroxymethyl-ivacaftor (M1) to a lesser extent than ivacaftor.
Istovremena primjena s ketokonazolom, jakim inhibitorom CYP3A, povećala je izloženost ivakaftoru (mjerenu kao površina ispod krivulje [AUC]) 8,5 puta, i povećala izloženost hidroksimetil-ivakaftoru (M1) u manjoj mjeri nego ivakaftoru.
Co-administration with medicinal products that are potent inhibitors of the UGT2B7 enzyme (for example, diclofenac, fluconazole, medroxyprogesterone acetate, meclofenamic acid) may significantly increase the exposure to nalmefene.
Istodobna primjena lijekova koji su snažni inhibitori enzima UGT2B7 (na primjer, diklofenak, flukonazol, medroksiprogesteron acetat, meklofenamična kiselina) može značajno povećati izloženost nalmefenu.
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Istovremena primjena s lijekovima koji su supstrati izoenzima CYP3A4 citokroma P450 i imaju uzak terapijski raspon (npr. kvetiapin, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralno primijenjen midazolam (za mjere opreza kod parenteralno primijenjenog midazolama, vidjeti dio 4.5) i alkaloidi ergota, osobito ergotamin, dihidroergotamin, ergonovin, metilergonovin) (vidjeti dio 4.5).
Co-administration with medicinal products that increase serum sodium concentration
Istovremena primjena s lijekovima koji povećavaju serumsku koncentraciju natrija
Co-administration with medicinal products that induce 3A4 activity may reduce the efficacy of Instanyl.
Istovremena primjena lijekova koji induciraju 3A4 aktivnost može smanjiti djelotvornost Instanyla.
Co-administration with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) (see section 4.5).
Ako se istodobno primjenjuju lijekovi čiji se klirens velikim dijelom odvija putem CYP3A4/5 i kod kojih su povišene koncentracije u plazmi povezane s ozbiljnim i/ili po život opasnim nuspojavama poput peroralno primijenjenog midazolama i triazolama, bepridila, pimozida, lumefantrina, halofantrina, inhibitora tirozin kinaze, simvastatina, lovastatina, kvetiapina, alfuzosina, silodosina i derivata ergota (dihidroergotamina, ergonovina, ergotamina, metilergonovina) (vidjeti dio 4.5).
Co-administration with midazolam may cause enhanced sedation or respiratory and cardiovascular depression.
Istodobna primjena s midazolamom može uzrokovati povećanu sedaciju ili respiratornu i kardiovaskularnu depresiju.
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4).
Istodobna primjena sa slabim induktorima CYP3A4/5 poput aprepitanta, prednizona i pioglitazona, moţe rezultirati blagim do umjerenim smanjenjem razina izavukonazola u plazmi, stoga istodobnu primjenu sa slabim induktorima CYP3A4/5 treba izbjegavati osim ako bi potencijalna korist nadmašila rizike (vidjeti dio 4.4).
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4).
Istodobna primjena sa slabim induktorima CYP3A4/5 poput aprepitanta, prednizona i pioglitazona, moţe rezultirati blagim do umjerenim smanjenjem razina izavukonazola u plazmi, stoga istodobnu primjenu sa slabim induktorima CYP3A4/5 treba izbjegavati osim ako bi potencijalna korist za nadmašila rizike (vidjeti dio 4.4).
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone, and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.5).
Istodobna primjena sa slabim induktorima CYP3A4/5 poput aprepitanta, prednizona i pioglitazona, moţe rezultirati blagim do umjerenim smanjenjem razina izavukonazola u plazmi pa istodobnu primjenu sa slabim induktorima CYP3A4/5 treba izbjegavati osim ako postoji potencijalna korist za bolesnika koja bi nadmašila rizike (vidjeti dio 4.5).
Co-administration with nitrates or nitric oxide donors (such as amyl nitrite) in any form including recreational drugs called ‘poppers’ (see section 4.5).
Istodobna primjena s nitratima ili donorima dušičnog oksida (kao što je amil-nitrit) u bilo kojem obliku, uključujući rekreacijske droge, tzv. „poppers“ (vidjeti dio 4.5).
Co-administration with other direct acting antivirals against HCV
Istodobna primjena s ostalim antiviroticima koji djeluju direktno na HCV
Co-administration with other direct-acting antivirals against HCV
Istodobna primjena s drugim antiviroticima koji djeluju izravno na HCV
co-administration with other doses
istovremenu primjenu s drugim
Co-administration with other HIV protease inhibitors (PIs)
Istodobna primjena s drugim inhibitorima HIV proteaza (PI; engl. protease inhibitor)
Co-administration with other treatments for hyponatraemia and medicinal products that increase serum sodium concentration
Istodobna primjena s drugim načinima liječenja hiponatremije i lijekovima koji povećavaju koncentraciju serumskog natrija
Co-administration with PDE 5 inhibitors (such as sildenafil, tadalafil, vardenafil) (see section 4.5).
Istodobna primjena s inhibitorima PDE-5 (kao što su sildenafil, tadalafil, vardenafil) (vidjeti dio 4.5).